MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3233/jad-191173

Медицинская библиотека · Journal of Alzheimer's disease : JAD · 2020

Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.

Shiells Helen, Schelter Bjoern O, Bentham Peter, Baddeley Thomas C, Rubino Christopher M, Ganesan Harish, Hammel Jeffrey, Vuksanovic Vesna, Staff Roger T, Murray Alison D, Bracoud Luc, Wischik Damon J, Riedel Gernot, Gauthier Serge, Jia Jianping, Moebius Hans J, Hardlund Jiri, Kipps Christopher M, Kook Karin, Storey John M D, Harrington Charles R, Wischik Claude M

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Hydromethylthionine is a potent inhibitor of pathological aggregation of tau and TDP-43 proteins.

OBJECTIVE

To compare hydromethylthionine treatment effects at two doses and to determine how drug exposure is related to treatment response in bvFTD.

METHODS

We undertook a 52-week Phase III study in 220 bvFTD patients randomized to compare hydromethylthionine at 200 mg/day and 8 mg/day (intended as a control). The principal outcomes were change on the Addenbrookes Cognitive Examination - Revised (ACE-R), the Functional Activities Questionnaire (FAQ), and whole brain volume. Secondary outcomes included Modified Clinical Global Impression of Change (Modified-CGIC). A population pharmacokinetic exposure-response analysis was undertaken in 175 of the patients with available blood samples and outcome data using a discriminatory plasma assay for the parent drug.

RESULTS

There were no significant differences between the two doses as randomized. There were steep concentration-response relationships for plasma levels in the range 0.3-0.6 ng/ml at the 8 mg/day dose on clinical and MRI outcomes. There were significant exposure-dependent differences at 8 mg/day for FAQ, Modified-CGIC, and whole brain atrophy comparing patients with plasma levels greater than 0.346 ng/ml with having minimal drug exposure. The exposure-response is biphasic with worse outcomes at the high concentrations produced by 200 mg/day.

CONCLUSIONS

Hydromethylthionine has a similar concentration-response profile for effects on clinical decline and brain atrophy at the 8 mg/day dose in bvFTD as recently reported in AD. Treatment responses in bvFTD are predicted to be maximal at doses in the range 20-60 mg/day. A confirmatory placebo-controlled trial is now planned.

Для цитирования: Shiells Helen, Schelter Bjoern O, Bentham Peter, Baddeley Thomas C, Rubino Christopher M, Ganesan Harish, Hammel Jeffrey, Vuksanovic Vesna, Staff Roger T, Murray Alison D, Bracoud Luc, Wischik Damon J, Riedel Gernot, Gauthier Serge, Jia Jianping, Moebius Hans J, Hardlund Jiri, Kipps Christopher M, Kook Karin, Storey John M D, Harrington Charles R, Wischik Claude M. Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.. Journal of Alzheimer's disease : JAD. 2020. DOI: 10.3233/jad-191173.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.